Siemens Healthineers, AiM team up; Procept completes study enrollment

Siemens Healthineers, AiM team up; Procept completes study enrollment

Siemens Healthineers’ MRI scanners would guide robotic neurosurgeries performed with AiM’s platform. Elsewhere, Procept finished enrollment in a study of its aquablation treatment in prostate cancer.

Aquablation Study Receives IDE Approval in Low-Grade Prostate Cancer

Enrollment for the WATER IV study evaluating aquablation vs radical prostatectomy has concluded, with primary end point results planned by spring 2027.

Procept secures FDA IDE for Aquablation and completes WATER IV study enrolment

Procept BioRobotics has received a second FDA IDE to allow another randomised study of its Aquablation therapy.The post Procept secures FDA IDE for Aquablation and completes WATER IV study enrolment appeared first on Medical Device Network.